Cancer Biology & Medicine

Papers
(The H4-Index of Cancer Biology & Medicine is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Multiplex imaging reveals the architecture of the tumor immune microenvironment133
Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity66
Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era42
Peptide drugs: a new direction in cancer immunotherapy42
The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study39
Hot issues in triple-negative breast cancer37
Drug clinical trials on high-grade gliomas: challenges and hopes34
Metabolic regulation of innate immunity in cancer immunotherapy32
Highlighted multi-modifications of enzymes: a novel succinylation mediated by histone acetyltransferase 1 in tumors32
Recent advances in the systemic treatment of gastrointestinal stromal tumors24
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy23
The interplay between H3K36 methylation and DNA methylation in cancer20
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer19
Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies19
Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells19
Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion via integrin/BRAF/TAK1/ERK/ETV4 signaling19
Evolving molecular subtyping of breast cancer advances precision treatment18
Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives18
DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation18
0.094913005828857